Upwards Drift of Cerebrospinal Fluid Amyloid-β 42 over Twelve Years in a Consecutive Clinical Cohort
Research output: Contribution to journal › Journal article › Research › peer-review
Amyloid-β 1-42 (Aβ1-42) measured in the cerebrospinal fluid (CSF) can be used as a diagnostic biomarker for Alzheimer's disease (AD) but an upward drift when using the INNOTEST ELISA has been suggested. We investigated the upwards drift of Aβ1-42 levels over a period of twelve years in a consecutive memory clinic cohort. We found a significant increase in Aβ1-42 from 2008 to 2019 independent of changes in tau. New methods for the quantification of CSF Aβ1-42 levels are being implemented but awareness of this upwards drift is crucial during the diagnostic work-up and when selecting historical samples for research.
| Original language | English |
|---|---|
| Journal | Journal of Alzheimer's Disease |
| Volume | 81 |
| Issue number | 4 |
| Pages (from-to) | 1369-1373 |
| ISSN | 1387-2877 |
| DOIs | |
| Publication status | Published - 2021 |
Bibliographical note
Funding Information:
This work is supported by the Simon Spies Foundation, Absalon Foundation, The Danish Order of Freemasons - Grand Lodge of Denmark, and Ellen Mørchs Fond.
Publisher Copyright:
© 2021-IOS Press. All rights reserved.
- Alzheimer's disease, amyloid-β 42, biomarker, cerebrospinal fluid
Research areas
ID: 301627888